Pulmonology
Cipla Launches Generic Idiopathic Pulmonary Fibrosis Drug Nintedanib In India
Cipla Launches Nintib
Cipla Launches Generic Nintedanib in India
New Delhi: Pharma major Cipla on Tuesday said it has launched generic Nintedanib used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) under the brand name 'Nintib' in India.
Available as 100 mg and 150 mg capsules, the launch marks another milestone in the company's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people, Cipla said in a statement.
In line with its endeavour of enabling effective and affordable management of IPF, Nintib is priced at Rs 69 (100 mg) and Rs 85 (150 mg) per capsule, it added.
Related Articles
- Read also: CDSCO committee nod to Cipla, Optimus phase 4 trials of COVID drug favipiravir
IPF is a chronic progressive form of lung disease with an average survival rate of three to five years if left untreated. It is characterised by scarring in the lungs, wherein the lung tissue becomes stiff and thick, Cipla said.
- Read also: Cipla gets USFDA nod for Dimethyl Fumarate DR Capsules to treat multiple sclerosis
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!